Table 1.
Effects of melatonin supplementation therapy (adding in oocytes culture or orally administered to patients) during ART.
| Authors | Species | Melatonin in vitro/in vivo |
Patients number (tot) | Intervention/control number |
Technique | Significant outcomes (p < 0.05) |
|---|---|---|---|---|---|---|
| Lord et al. 2013 [36] | Mouse | Adding M in oocyte culture medium | (i) Increased number of oocytes that reached blastocyst stage | |||
|
| ||||||
| Kang et al. 2009 [37] | Porcine | Adding M in oocyte culture medium | (i) Increased mature oocyte | |||
|
| ||||||
| Tamura et al. 2008 [32] | Human | Orally administered M (3 mg/day) | 115 | 56 versus 56 nontreated 1° cycle versus treated 2° cycle |
IVF-ET | (i) Improved fertilization rate |
| M (3 mg/day) versus Vit. E (600 mg/day) versus M + Vit. E (3 mg + 600 mg/day) | 18 | 59 versus 59 nontreated 1° cycle versus nontreated 2° cycle | (i) Reduced 8-OHdG in FF (ii) Increased in FF in treated patient. |
|||
|
| ||||||
| Kim et al. 2013 [33] | Human | Adding M in oocyte culture medium | 111 | 62/49 | IVM IVF-ET |
(i) Increased mature oocyte (ii) Increased implantation |
|
| ||||||
| Batioglu et al. 2012 [39] | Human | Orally administered M (3 mg/day) | 85 | 40/45 | IVF-ET | (i) Increased mature oocyte (ii) Increased good quality embryos |
|
| ||||||
| Eryilmaz et al. 2011 [40] | Human | Orally administered M (3 mg/day) | 60 | 30/30 | IVF-ET | (i) Increased mature oocyte (ii) Increased good quality embryos |
|
| ||||||
| Nishihara et al. 2014 [41] | Human | Orally administered M (3 mg/day) | 97 | 97/97 (control of itself) |
IVF ICSI |
(i) Improved fertilization with ICSI (ii) Improved fertilization in poor responder (iii) Improved good quality embryos |
M: melatonin; Vit. E: vitamin E; IVF: in vitro fertilization; ET: embryo transfer; IVM: in vitro maturation; ICSI: intracytoplasmic sperm injection; 8-OHdG: 8-hydroxy-2-deoxyguanosine.